At the time of COVID-19 diagnosis, 34.3% of patients were receiving active CLL therapy, most commonly Bruton tyrosine kinase inhibitors (BTKi’s) (54.9%). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.